MeiraGTx Corp (MGTX) Long-Term Debt to Capital Ratio

Corporate emblem and logo of MeiraGTx Corp (MGTX)

The daily price chart for MeiraGTx Holdings plc (MGTX) allows for an assessment of the company's stability, as it has established a reliable biomaterial delivery system through its hubs, ensuring high margins. The current figure is 0.54. The business specializes in therapies for rare pathologies, utilizing in-house vector production capabilities to accelerate drug time-to-market. The presence of certified manufacturing plants minimizes development risks and attracts strategic partners.

MeiraGTx PLC (MGTX): Long-Term Debt to Equity from 07/04/2022 to 11/01/2026

Comprehensive metric breakdowns and analytics for MeiraGTx Holdings plc (MGTX)

- current price and projected stock value:
Share Price MeiraGTx Holdings|MGTX - Price Target Chart
- market capitalization details:
Market Capitalization MeiraGTx Holdings|MGTX - Enterprise Value
- issuer book value statistics:
Book Value per Share MeiraGTx|MGTX - Company Book Value|Market Cap to Net Assets Ratio meiragtx.com|MGTX - Company Total Assets
- debt and solvency information:
Debt to Capital MeiraGTx Holdings plc|MGTX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient meiragtx.com|MGTX - Company Debts|Debt to Net Assets Ratio MeiraGTx Holdings|MGTX - Company Long-Term Debts|Company Short-Term Debts MeiraGTx|Critical Liquidity meiragtx.com
- net income and valuation ratios data:
MGTX - Net Income
Comprehensive company analysis:MeiraGTx Holdings - MGTX
Original product of MeiraGTx

This indicator assesses the issuer's financial stability by determining the proportion of debt with a maturity exceeding one year relative to the company's equity. By analyzing the current long-term debt-to-equity ratio, an investor can discern the level of leverage required by MeiraGTx Holdings plc (MGTX) to finance the capital-intensive implementation of automated GMP platforms and robotic viral vector synthesis systems.

Key competitors

Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Equity Qiagen Group (QGEN)|Isis Pharmaceuticals - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RGEN (Repligen Corporation)|Long-Term Debt to Capital aviditybiosciences.com RNA|CRSP - Long-Term Debt to Equity|GeneDx Holdings (WGS) - Long-Term Debt to Equity Ratio|RARE: Long-Term Debt to Capital|Long-Term Liabilities to Capital Beam Tx (BEAM)|SRPT (Sarepta Therapeutics, Inc.) - Long-Term Debt to Capital|twistbioscience.com (TWST) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity 10x Genomics (TXG)|NTLA (Intellia Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital STOK (Stoke)|Long-Term Debt to Capital BioLife BLFS|Wave Life Sciences - Long-Term Debt to Capital|Long-Term Indebtedness to Equity mazetx.com (MAZE)|SION (Sionna Therapeutics) - Long-Term Debt to Equity Ratio|PRME: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Ratio TSHA|Long-Term Debt to Capital Ratio QURE (uniQure Pharma)|Long-Term Debt to Equity Ratio RGNX (REGENXBIO Inc.)|SLDB (solidbio.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital OCGN (Ocugen)|Long-Term Debt to Capital Coefficient PACB|BNTC - Long-Term Debt to Equity|Long-Term Liabilities to Capital Design Corp|Rocket Pharmaceuticals (RCKT) - Long-Term Debt to Equity|FDMT (4dmoleculartherapeutics.com) - Long-Term Debt to Equity|LXEO (Lexeo Therapeutics Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Ratio KRRO (Korro Bio, Inc)|Long-Term Debt to Capital EDIT|Ratio of Long-Term Indebtedness to Capital Silence Therapeutics Corp|Long-Term Debt to Equity ProQR Therapeutics PRQR|CDXS: Long-Term Debt to Capital Ratio|Sangamo Therapeutics, Inc. - Long-Term Debt to Capital|Long-Term Indebtedness to Equity Nautilus Biotechnology (NAUT)|Metagenomi, Inc (MGX) - Long-Term Debt to Equity|DTIL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio GBIO|BOLD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Exicure, Inc. (XCUR)|IMNN: Long-Term Liabilities to Equity|Long-Term Debt to Equity Phio Pharmaceuticals Corp. PHIO|Mustang Bio Inc - Long-Term Debt to Equity|TransCode - Long-Term Debt to Capital|Bionano Genomics, Inc. (BNGO) - Long-Term Debt to Equity Ratio|Applied DNA Sciences, Inc. (APDN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio bluebird bio Inc.|IPA (ImmunoPrecise Antibodies Ltd) - Long-Term Debt to Capital|OMGA - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio OMIC (Singular Genomics Systems)|Long-Term Loans to Capital Ratio RGLS|Syros Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|TBIO: Long-Term Debt to Capital Ratio|TRACON - Long-Term Debt to Capital|UBX (Unity Biotechnology, Inc) - Long-Term Debt to Capital Ratio